Cardlytics earnings beat by $0.26, revenue fell short of estimates

Cardlytics (CDLX) reported a Q2 EPS beat at $-0.13, surpassing analyst estimates, but its $63.2M revenue fell short of consensus. The company's Q3 2025 revenue guidance of $52.20M-$58.20M was notably weaker than the $67.33M analyst consensus, signaling continued headwinds. This outlook, combined with a 74.64% stock decline over the past year and an InvestingPro 'weak performance' financial health rating, underscores persistent challenges for the firm.

Analysis

Cardlytics (CDLX) presented a mixed but predominantly negative second-quarter report. While the company posted an earnings per share of $-0.13, significantly outperforming the analyst consensus of $-0.39 by $0.26, this was undermined by a revenue miss and a severely weak forward-looking guidance. Quarterly revenue came in at $63.2 million, slightly below the $64.06 million estimate. More critically, the third-quarter revenue projection of $52.20 million to $58.20 million falls substantially short of the $67.33 million analyst consensus, signaling anticipated operational headwinds and a deteriorating sales outlook. This weak guidance is consistent with the stock's performance, which has declined 74.64% over the past 12 months, and is further corroborated by two recent negative EPS revisions and an InvestingPro financial health score of "weak performance."

Key Decisions for Investors

• Investors should prioritize the weak Q3 revenue guidance over the historical Q2 EPS beat, as the forward-looking statement suggests fundamental business challenges are intensifying.
• Given the stock's 74.64% decline in the last year and its 'weak performance' financial health rating, the risk profile remains exceptionally high, warranting extreme caution for any new or existing positions.
• A potential turnaround would require evidence of revenue stabilization, making future earnings reports and any revisions to guidance critical indicators to monitor before considering an investment.